Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study.

SUPPLEMENTARY MATERIAL

Country	Number of patients N = 4465	Region	Number of patients	
Argentina	214			
Chile	68	Latin America	538 (12.0%)	
Mexico	217			
Colombia	39			
France	305			
Spain	208			
Germany	302			
Netherlands	129			
Romania	132		1677 (37.6%)	
Portugal	191	Europe and North America		
Hungary	100			
Italy	200			
US	98			
Canada	12			
UK	0			
India	209			
Japan	197		975 (21.8%)	
China	167	Asia		
Taiwan	202			
South Korea	200			
Egypt	288			
Morocco	285	Middle East and North Africa	1275 (28.6%)	
Lebanon	213	iviluale cast and North Africa		
Turkey	489			

Supplementary Table S1. Final number of patients per country and per region.

Supplementary Table S2. Socio-demographics and clinical characteristics, disease activity and disease burden with regard to the geographic area.

Gender (men)61.7%58.7%72.2%55.2%BMI (Kg/m²), mean (SD)27.2 (4.9)27.0 (5.7)23.8 (4.5)27.0 (5.3)Ever snoker38.8%911/673 (54.5%)35.1%34.4%Ever alcohol44.2%875/1674 (52.3%)44.4%20.9%University education217/537 (40.4%)600/1674 (35.8%)55.3%36.0%Fibromyalgia (fheumatologist's opinion)29/537 (54.%)159/1676 (55.%)1.8%15.2%Fibromyalgia (fiRST)127/527 (24.1%)343/1584 (21.7%)101/856 (11.8%)204/1160 (17.6%)Diagnosis-**60.3%62.6%64.4%-pSpA65.5%6.1%14.2%12.4%-PSA32.7%29.2%16.9%15.9%-Nus SpA + others4.6%2.4%3.5%5.4%-Juu-SpA + others4.8%2.0%2.9%1.9%Symptom duration (years), mean (SD)15.3 (11.2)17.5 (12.5)11.3 (9.8)2.1 (9.6)Diagnosis delay (years), mean (SD)7.5 (9.2)7.2 (9.6)5.3 (8.0)5.7 (7.4)HL-B27 positive283/397 (59.9%)818/1234 (66.3%)623/775 (80.4%)387/144 (54.2%)Fist or second-degreer elatives of SpA*24/473 (50.7%)857/1539618/936 (66.0%)802/1212 (66.2%)Sacroillits on x-ray240/473 (50.7%)857/153951.3%7.8%Sold ever (confirmed by endoscopy)5.4%61.9%3.0%7.8%Sold ever (confirmed by a Dermatologist)		Latin America	Europe and North	Asia	Middle East and North
Age, mean (SD) 46.2 (13.8) 47.7 (13.6) 40.7 (14.7) 42.3 (12.8) Gender (men) 61.7% 58.7% 72.2% 55.2% BMI (Kg/m), mean (SD) 27.2 (4.9) 27.0 (5.7) 23.8 (4.5) 27.0 (5.7) Ever smoker 38.8% 911/1673 (54.5%) 35.1% 34.4% Ever alcohol 44.2% 875/1674 (52.3%) 44.4% 20.9% University education 217/537 (40.4%) 600/1674 (35.8%) 55.3% 36.0% Fibromyalgia (riteuratologist's opinion) 29/537 (5.4%) 159/1676 (9.5%) 1.8% 15.2% Diagnosis - ax5pA 5.13% 60.3% 62.6% 64.4% - pSpA 6.5% 6.1% 14.2% 12.4% - pSpA 5.3% 36.0% 2.9% 15.9% - rue SpA 2.0% 2.9% 1.9% 5.4% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosis delaty (years), mean (SD) 7.5 (9.2)		N = 538	America	N = 975	Africa
Gender (men)61.7%58.7%72.2%55.2%BMI (Kg/m²), mean (SD)27.2 (4.9)27.0 (5.7)23.8 (4.5)27.0 (5.3)Ever snoker38.8%911/673 (54.5%)35.1%34.4%Ever alcohol44.2%875/1674 (52.3%)44.4%20.9%University education217/537 (40.4%)600/1674 (35.8%)55.3%36.0%Fibromyalgia (fheumatologist's opinion)29/537 (54.%)159/1676 (55.%)1.8%15.2%Fibromyalgia (fiRST)127/527 (24.1%)343/1584 (21.7%)101/856 (11.8%)204/1160 (17.6%)Diagnosis-a\$\$pA65.5%6.1%44.4%2.0%-a\$\$pA51.3%60.3%62.6%64.4%-pSpA65.5%6.1%14.2%12.4%-pSpA32.7%29.2%16.9%15.9%-ak\$pA15.3 (11.2)17.5 (12.5)11.3 (9.8)12.1 (9.6)Diagnosis delay (years), mean (SD)7.5 (9.2)7.2 (9.6)5.3 (8.0)5.7 (7.4)HL+B27 positive283/937 (59.9%)818/1234 (66.3%)623/775 (80.4%)387/144 (54.2%)Fist or second-degreer elatives of \$pA*2.4%75.7%82.1%78.6%Sacroilitis on ×ray240/473 (50.7%)857/153913.8(0%7.8%Poriasis ever (confirmed by endoscopy)5.4%61.1%3.0%7.8%SolDaden ever17.8%31.3%61.6%63.9%66.4%SolDaden ever (confirmed by a Dermatologist)52.6%67.4%52.1%			N = 1677		N = 1275
BMI (Kg/m²), mean (SD) 27.2 (4.9) 77.0 (5.7) 23.8 (4.5) 27.0 (5.3) Ever smoker 38.8% 911/1673 (54.5%) 34.4% 20.9% Ever alcohol 44.2% 875/1674 (52.3%) 44.4% 20.9% University education 217/537 (40.4%) 600/1674 (35.8%) 55.3% 36.0% Fibromyalgia (FiRST) 127/527 (24.1%) 159/1676 (9.5%) 1.8% 15.2% Diagnosi 127/527 (24.1%) 434/1584 (21.1%) 101/856 (11.8%) 20/4/160 (17.6%) Diagnosi 5.3% 60.3% 6.1% 14.2% 12.4% - sSpA 6.5% 6.1% 14.2% 12.4% - sASpA 2.3% 2.9% 1.9% 5.4% - Jux-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 15.3 (11.2) 17.3 (12.5) 11.3 (19.8) 12.1 (9.6) Diagnois delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) Kist or second-degree relatives of SpA* 29.4% 38.0% <t< th=""><th>Age, mean (SD)</th><th>46.2 (13.8)</th><th>47.7 (13.6)</th><th>40.7 (14.7)</th><th>42.3 (12.8)</th></t<>	Age, mean (SD)	46.2 (13.8)	47.7 (13.6)	40.7 (14.7)	42.3 (12.8)
Ever smoker 38.8% 911/1673 (54.5%) 35.1% 34.4% Ever alcohol 44.2% 675/1674 (52.3%) 44.4% 20.9% University education 29/537 (5.4%) 159/1676 (9.5%) 1.8% 15.2% Fibromyalgia (rheumatologist's opinion) 29/537 (5.4%) 159/1676 (9.5%) 1.8% 15.2% Diagnosis 127/537 (24.1%) 343/1584 (21.7%) 101/856 (11.8%) 204/1160 (17.6%) - axSpA 6.3% 60.3% 62.6% 64.4% - pSpA 6.5% 6.1% 14.2% 12.4% - PsA 32.7% 29.2% 16.9% 15.9% - Nu-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-B27 positive 238/397 (59.9%) 818/123 (66.3%) 6623/775 (80.4%) 38.7% Fist or second-degreer elatives of SpA* 29.4% 38.0% 72.5% 35.1% 31.3% Sarcrolilitis on x-ray	Gender (men)	61.7%	58.7%	72.2%	55.2%
Ever alcohol 44.2% 875/1674 (52.3%) 44.4% 20.9% University education 217/537 (40.4%) 600/1674 (53.8%) 55.3% 36.0% Fibromyalgia (FiRST) 29/537 (5.4%) 159/1676 (9.5%) 1.8% 15.2% Fibromyalgia (FiRST) 127/527 (24.1%) 343/1584 (21.7%) 101/856 (11.8%) 204/1160 (17.6%) Diagnosis - axSpA 60.3% 62.6% 64.4% - pSpA 65.5% 6.1% 14.2% 12.4% - wispA - others 32.7% 29.2% 16.9% 15.9% - keA + IBD 4.6% 2.4% 3.5% 5.4% - Jux-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-827 positive 238/397 (59.9%) 881/1234 (66.3%) 623/775 (80.4%) 38/7/14 (54.2%) First or second-degree relatives of SpA* 240/473 (50.7%) 587/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% <td< td=""><td>BMI (Kg/m²), mean (SD)</td><td>27.2 (4.9)</td><td>27.0 (5.7)</td><td>23.8 (4.5)</td><td>27.0 (5.3)</td></td<>	BMI (Kg/m²), mean (SD)	27.2 (4.9)	27.0 (5.7)	23.8 (4.5)	27.0 (5.3)
University education 217/537 (40.4%) 600/1674 (35.8%) 55.3% 36.0% Fibromyalgia (rheumatologist's opinion) 29/537 (5.4%) 159/1676 (9.5%) 1.8% 15.2% Fibromyalgia (riFINT) 127/527 (24.1%) 343/1584 (21.7%) 101/856 (11.8%) 204/1160 (17.6%) Diagnosi - a SpA 60.3% 62.6% 64.4% - pSpA 60.5% 6.1% 14.2% 12.4% - PSA 32.7% 29.2% 16.9% 5.4% - VSpA + others 4.6% 2.4% 3.5% 5.4% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosit delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7% Stacrolifitis on x-ray 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacrolifitis on x-ray 240/473 (50.7%) 857/159 (55.7%) 618/936 (66.0%) 82/122 (66.2%) Uveitis ever 19	Ever smoker	38.8%	911/1673 (54.5%)	35.1%	34.4%
Fibromyalgia (rheumatologist's opinion) 29/537 (5.4%) 159/1676 (9.5%) 1.8% 15.2% Fibromyalgia (rheumatologist's opinion) 127/527 (24.1%) 343/1584 (21.7%) 101/856 (11.8%) 204/1160 (17.6%) Diagnosic - axSpA 60.3% 62.6% 64.4% - pSpA 61.3% 60.3% 62.6% 64.4% - PSA 6.5% 6.1% 14.2% 12.4% - NeA + IBD 4.6% 2.4% 3.5% 5.4% - Jux-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) Diagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 387/714 (54.2%) Symptom duration (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 387/714 (54.2%) Stari involvement (according to the rheumatologist) 766.4% 78.6% 61.3% 623/775 (80.4%) 387/714 (54.2%) Stari involvement (according to the rheumatologist) 75.4% 38.0% 62.1% 78.6% Stari involvement (according to the rheumatologist) 5.4% <td< td=""><td>Ever alcohol</td><td>44.2%</td><td>875/1674 (52.3%)</td><td>44.4%</td><td>20.9%</td></td<>	Ever alcohol	44.2%	875/1674 (52.3%)	44.4%	20.9%
Fibromyalgia (FiRST) 127/527 (24.1%) 343/1584 (21.7%) 101/856 (11.8%) 204/1160 (17.6%) Diagnosis - axSpA 51.3% 60.3% 62.6% 64.4% - pSpA 5.5% 6.1% 14.2% 12.4% - PSA 32.7% 29.2% 16.9% 15.9% - ReA + IBD 4.6% 2.4% 3.5% 5.4% - Juv-SpA + others 4.8% 2.0% 2.9.2% 1.9% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-B27 positive 238/397 (59.9%) 818/1234 (66.3%) 623/775 (80.4%) 380/714 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacrollittis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 30.2% 78.6% BD ever (confirmed by endoscopy) 5.4%	University education	217/537 (40.4%)	600/1674 (35.8%)	55.3%	36.0%
Diagnosis - axSpA 51.3% 60.3% 62.6% 64.4% - pSpA 6.5% 6.1% 14.2% 12.4% - PSA 32.7% 29.2% 16.9% 15.9% - ReA + IBD 4.6% 2.4% 3.5% 5.4% - Jux-SpA + others 4.8% 2.0% 2.9.9% 1.9% Symptom duration (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) Piagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-827 positive 238/397 (59.9%) 818/1234 (66.3%) 623/775 (80.4%) 387/14 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacroillitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% 17.6% 30.0% 7.8% P	Fibromyalgia (rheumatologist's opinion)	29/537 (5.4%)	159/1676 (9.5%)	1.8%	15.2%
- axSpA 51.3% 60.3% 62.6% 64.4% - pSpA 6.5% 6.1% 14.2% 12.4% - PsA 32.7% 29.2% 16.9% 5.5% - ReA + IBD 4.6% 2.4% 3.5% 5.4% - Juv-SpA + others 4.6% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) PluA-B22 positive 238/397 (59.9%) 818/1234 (66.3%) 623/75 (80.4%) 387/14 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacroillitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% Current coDMARDs ever 53.9% 29.3% 44.8% 31.3%	Fibromyalgia (FiRST)	127/527 (24.1%)	343/1584 (21.7%)	101/856 (11.8%)	204/1160 (17.6%)
- pSpA 6.5% 6.1% 14.2% 12.4% - PsA 32.7% 29.2% 16.9% 15.9% - ReA + IBD 4.6% 2.4% 3.5% 5.4% - Juv-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-B27 positive 238/397 (59.9%) 818/1234 (66.3%) 623/775 (80.4%) 387/714 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacrollitits on x-ray 19.1% 17.6% 17.6% 13.2% Uveits ever 19.1% 17.6% 61.6% 78.6% Scondifities on x-ray 68.6% 60.0% 74.7% 61.6% Scondifities on x-ray 54.9% 61.9%<	Diagnosis				
- PsA 32.7% 29.2% 16.9% 15.9% - ReA + IBD 4.6% 2.4% 3.5% 5.4% - Juv-SpA + others 4.6% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-B27 positive 238/397 (59.9%) 818/1234 (66.3%) 623/775 (80.4%) 387/714 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacroillitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% 17.6% 13.2% 13.2% BD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.6% bDMARDs ever 52.6%	- axSpA	51.3%	60.3%	62.6%	64.4%
- ReA + IBD 4.6% 2.4% 3.5% 5.4% - Juv-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacroillitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% 17.6% 17.6% 13.2% IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% cSDMARDs ever 86.8% 60.0% 74.7% 61.6% 66.9% bDMARDs ever 52.6% 67.4% 52.1% 56.9% 63.4% Current sDMARDs 33.5% 56.2% 38.3% 46.4% 31.3% <	- pSpA	6.5%	6.1%	14.2%	12.4%
Juv-SpA + others 4.8% 2.0% 2.9% 1.9% Symptom duration (years), mean (SD) 15.3 (11.2) 17.5 (12.5) 11.3 (9.8) 12.1 (9.6) Diagnosis delay (years), mean (SD) 7.5 (9.2) 7.2 (9.6) 5.3 (8.0) 5.7 (7.4) HLA-B27 positive 238/397 (59.9%) 818/1234 (66.3%) 623/775 (80.4%) 387/714 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.66% Sacroillitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% 17.6% 17.6% 13.2% IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% csDMARDs ever 52.6% 67.4% 52.1% 56.9% 6.9% Current sDMARDs 33.5% 56.2% 38.3% 46.4% <	- PsA	32.7%	29.2%	16.9%	15.9%
Symptom duration (years), mean (SD)15.3 (11.2)17.5 (12.5)11.3 (9.8)12.1 (9.6)Diagnosis delay (years), mean (SD)7.5 (9.2)7.2 (9.6)5.3 (8.0)5.7 (7.4)HLA-B27 positive238/397 (59.9%)818/1234 (66.3%)623/775 (80.4%)387/714 (54.2%)First or second-degree relatives of SpA*29.4%38.0%29.5%35.1%Axial involvement (according to the rheumatologist)66.4%75.7%82.1%78.6%Sacroillitis on x-ray240/473 (50.7%)857/1539 (55.7%)618/936 (66.0%)802/1212 (66.2%)Uveitis ever19.1%17.6%17.6%3.0%7.8%IBD ever (confirmed by endoscopy)5.4%6.1%3.0%7.8%Psoriasis ever (confirmed by a Dermatologist)178/537 (33.1%)31.4%20.0%16.7%csDMARDs ever86.8%60.0%74.7%61.6%bDMARDs ever53.9%29.3%44.8%31.3%Current sDMARDs33.5%56.2%38.3%46.4%NSAlDs alone22.1%21.6%24.2%26.3%CRP mg/L, mean (SD)22.7 (49.5)6.9 (13.4)13.8 (28.5)12.7 (23.1)CRP 26 mg/L284/525 (54.1%)540/1673 (32.3%)428/973 (44.0%)634/1265 (50.1%)	- ReA + IBD	4.6%	2.4%	3.5%	5.4%
Diagnosis delay (years), mean (SD)7.5 (9.2)7.2 (9.6)5.3 (8.0)5.7 (7.4)HLA-B27 positive238/397 (59.9%)818/1234 (66.3%)623/775 (80.4%)387/714 (54.2%)First or second-degree relatives of SpA*29.4%38.0%29.5%35.1%Axial involvement (according to the rheumatologist)66.4%75.7%82.1%78.6%Sacroillitis on x-ray240/473 (50.7%)857/1539 (55.7%)618/936 (66.0%)802/1212 (66.2%)Uveitis ever19.1%17.6%17.6%13.2%IBD ever (confirmed by endoscopy)5.4%6.1%3.0%7.8%Psoriasis ever (confirmed by a Dermatologist)178/537 (33.1%)31.4%20.0%16.7%csDMARDs ever86.8%60.0%74.7%61.6%bDMARDs ever52.6%67.4%52.1%56.9%Current csDMARDs33.5%56.2%38.3%46.4%NSAIDs alone22.1%21.6%24.2%26.3%CRP mg/L, mean (SD)22.7 (49.5)6.9 (13.4)13.8 (28.5)12.7 (23.1)CRP ≥6 mg/L284/525 (54.1%)540/1673 (32.3%)428/973 (44.0%)634/1265 (50.1%)	- Juv-SpA + others	4.8%	2.0%	2.9%	1.9%
HLA-B27 positive 238/397 (59.9%) 818/1234 (66.3%) 623/775 (80.4%) 387/714 (54.2%) First or second-degree relatives of SpA* 29.4% 38.0% 29.5% 35.1% Axial involvement (according to the rheumatologist) 66.4% 75.7% 82.1% 78.6% Sacroiliitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% 17.6% 17.6% 13.2% IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% csDMARDs ever 52.6% 67.4% 52.1% 56.9% 6.69% Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current sDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%) <td>Symptom duration (years), mean (SD)</td> <td>15.3 (11.2)</td> <td>17.5 (12.5)</td> <td>11.3 (9.8)</td> <td>12.1 (9.6)</td>	Symptom duration (years), mean (SD)	15.3 (11.2)	17.5 (12.5)	11.3 (9.8)	12.1 (9.6)
First or second-degree relatives of SpA*29.4%38.0%29.5%35.1%Axial involvement (according to the rheumatologist)66.4%75.7%82.1%78.6%Sacroiliitis on x-ray240/473 (50.7%)857/1539 (55.7%)618/936 (66.0%)802/1212 (66.2%)Uveitis ever19.1%17.6%17.6%13.2%IBD ever (confirmed by endoscopy)5.4%6.1%3.0%7.8%Psoriasis ever (confirmed by a Dermatologist)178/537 (33.1%)31.4%20.0%16.7%csDMARDs ever86.8%60.0%74.7%61.6%bDMARDs ever52.6%67.4%52.1%56.9%Current csDMARDs53.9%29.3%44.8%31.3%Current bDMARDs33.5%56.2%38.3%46.4%NSAIDs alone22.1%21.6%24.2%26.3%CRP mg/L, mean (SD)22.7 (49.5)6.9 (13.4)13.8 (28.5)12.7 (23.1)CRP ≥6 mg/L284/525 (54.1%)540/1673 (32.3%)428/973 (44.0%)634/1265 (50.1%)	Diagnosis delay (years), mean (SD)	7.5 (9.2)	7.2 (9.6)	5.3 (8.0)	5.7 (7.4)
Axial involvement (according to the rheumatologist)66.4%75.7%82.1%78.6%Sacroiliitis on x-ray240/473 (50.7%)857/1539 (55.7%)618/936 (66.0%)802/1212 (66.2%)Uveitis ever19.1%17.6%17.6%13.2%IBD ever (confirmed by endoscopy)5.4%6.1%3.0%7.8%Psoriasis ever (confirmed by a Dermatologist)178/537 (33.1%)31.4%20.0%16.7%csDMARDs ever86.8%60.0%74.7%61.6%bDMARDs ever52.6%67.4%52.1%56.9%Current csDMARDs53.9%29.3%44.8%31.3%Current bDMARDs33.5%56.2%38.3%46.4%NSAIDs alone22.1%21.6%24.2%26.3%CRP mg/L, mean (SD)22.7 (49.5)6.9 (13.4)13.8 (28.5)12.7 (23.1)CRP ≥6 mg/L284/525 (54.1%)540/1673 (32.3%)428/973 (44.0%)634/1265 (50.1%)	HLA-B27 positive	238/397 (59.9%)	818/1234 (66.3%)	623/775 (80.4%)	387/714 (54.2%)
Sacroiliitis on x-ray 240/473 (50.7%) 857/1539 (55.7%) 618/936 (66.0%) 802/1212 (66.2%) Uveitis ever 19.1% 17.6% 17.6% 13.2% IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% csDMARDs ever 86.8% 60.0% 74.7% 61.6% bDMARDs ever 52.6% 67.4% 52.1% 56.9% Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	First or second-degree relatives of SpA*	29.4%	38.0%	29.5%	35.1%
Uveitis ever 19.1% 17.6% 17.6% 13.2% IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% csDMARDs ever 86.8% 60.0% 74.7% 61.6% bDMARDs ever 52.6% 67.4% 52.1% 56.9% Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	Axial involvement (according to the rheumatologist)	66.4%	75.7%	82.1%	78.6%
IBD ever (confirmed by endoscopy) 5.4% 6.1% 3.0% 7.8% Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% csDMARDs ever 86.8% 60.0% 74.7% 61.6% bDMARDs ever 52.6% 67.4% 52.1% 56.9% Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	Sacroiliitis on x-ray	240/473 (50.7%)	857/1539 (55.7%)	618/936 (66.0%)	802/1212 (66.2%)
Psoriasis ever (confirmed by a Dermatologist) 178/537 (33.1%) 31.4% 20.0% 16.7% csDMARDs ever 86.8% 60.0% 74.7% 61.6% bDMARDs ever 52.6% 67.4% 52.1% 56.9% Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	Uveitis ever	19.1%	17.6%	17.6%	13.2%
csDMARDs ever 86.8% 60.0% 74.7% 61.6% bDMARDs ever 52.6% 67.4% 52.1% 56.9% current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	IBD ever (confirmed by endoscopy)	5.4%	6.1%	3.0%	7.8%
bDMARDs ever 52.6% 67.4% 52.1% 56.9% Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	Psoriasis ever (confirmed by a Dermatologist)	178/537 (33.1%)	31.4%	20.0%	16.7%
Current csDMARDs 53.9% 29.3% 44.8% 31.3% Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	csDMARDs ever	86.8%	60.0%	74.7%	61.6%
Current bDMARDs 33.5% 56.2% 38.3% 46.4% NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	bDMARDs ever	52.6%	67.4%	52.1%	56.9%
NSAIDs alone 22.1% 21.6% 24.2% 26.3% CRP mg/L, mean (SD) 22.7 (49.5) 6.9 (13.4) 13.8 (28.5) 12.7 (23.1) CRP ≥6 mg/L 284/525 (54.1%) 540/1673 (32.3%) 428/973 (44.0%) 634/1265 (50.1%)	Current csDMARDs	53.9%	29.3%	44.8%	31.3%
CRP mg/L, mean (SD)22.7 (49.5)6.9 (13.4)13.8 (28.5)12.7 (23.1)CRP ≥6 mg/L284/525 (54.1%)540/1673 (32.3%)428/973 (44.0%)634/1265 (50.1%)	Current bDMARDs	33.5%	56.2%	38.3%	46.4%
CRP ≥6 mg/L284/525 (54.1%)540/1673 (32.3%)428/973 (44.0%)634/1265 (50.1%)	NSAIDs alone	22.1%	21.6%	24.2%	26.3%
	CRP mg/L, mean (SD)	22.7 (49.5)	6.9 (13.4)	13.8 (28.5)	12.7 (23.1)
ASDAS-CRP, mean (SD) 2.9 (1.3) 2.4 (1.1) 2.4 (1.1) 2.6 (1.1)	CRP ≥6 mg/L	284/525 (54.1%)	540/1673 (32.3%)	428/973 (44.0%)	634/1265 (50.1%)
	ASDAS-CRP, mean (SD)	2.9 (1.3)	2.4 (1.1)	2.4 (1.1)	2.6 (1.1)

ASDAS-CRP <1.3	60/523 (11.5%)	319/1642 (19.4%)	178/973 (18.3%)	164/1264 (13.0%)
ASDAS-CRP <2.1	155/523 (29.6%)	711/1642 (43.3%)	435/973 (44.7%)	424/1264 (33.5%)
PGA, mean (SD)	4.6 (3.0)	4.2 (2.7)	4.0 (2.5)	4.7 (2.6)
BASDAI, mean (SD)	4.4 (2.8)	3.9 (2.4)	3.4 (2.3)	3.9 (2.3)
BASFI, mean (SD)	3.8 (3.0)	3.1 (2.6)	2.1 (2.4)	3.2 (2.6)
ASAS-HI, mean (SD)	7.3 (4.9)	6.5 (4.4)	6.2 (4.7)	6.7 (4.6)
PERIPHERAL MANIFESTATIONS				
Peripheral joint disease in the past	79.9%	52.8%	61.4%	49.2%
Peripheral joint disease in the past confirmed by specific	73.4%	48.1%	53.1%	45.1%
investigations				
Root joints involvement in the past	49.1%	17.5%	57.4%	30.3%
Mid foot arthritis (tarsitis) in the past	23.6%	5.0%	9.1%	3.5%
Mid foot arthritis (tarsitis) in the past confirmed by specific	4.1%	2.3%	2.8%	1.0%
investigations				
Any enthesitis in the past	68.8%	37.1%	47.7%	41.3%
Any enthesitis in the past confirmed by specific investigations	24.3%	16.7%	16.2%	15.5%
Dactylitis in the past	25.5%	14.2%	17.1%	11.2%
Number of current swollen joints, mean (SD)	1.4 (3.0)	0.5 (1.8)	0.9 (2.8)	0.9 (4.6)
Any current swollen joint	189/536 (35.3%)	269/1675 (16.1%)	23.4%	19.8%
Number of current tender joints, mean (SD)	4.2 (8.2)	1.8 (4.5)	2.2 (5.9)	2.9 (6.7)
Any current tender joint	328/536 (61.2%)	604/1675 (36.1%)	38.6%	54.0%
Current MEI score, mean (SD)	5.2 (9.9)	1.4 (4.2)	1.1 (3.8)	3.6 (6.8)
Number of current enthesitis according to the MEI ⁺ , mean (SD)	1.6 (3.6)	0.3 (1.4)	0.2 (1.3)	1.0 (2.2)
Any current enthesitis according to the MEI ⁺	175/536 (32.6%)	182/1675 (10.9%)	7.6%	28.2%
Any current enthesitis according to the SPARCC Enthesitis Index	133/536 (24.8%)	118/1675 (7.0%)	4.1%	14.0%
Any current enthesitis according to the LEI	94/536 (17.5%)	88/1675 (5.2%)	2.9%	11.8%


All results are presented as mean (SD) and percentages for continuous and categorical variables, respectively.

*First or second-degree relatives with Ankylosing Spondylitis, psoriasis, uveitis, reactive arthritis or inflammatory bowel disease.

*Enthesis with a score >1 according to the MEI.


ASAS-HI: ASAS Health Index; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score; AxSpA: axial Spondyloarthritis; BASDAI: Bath Ankylosing Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; bDMARDs: biological disease-modifying antirheumatic drugs; BMI: body mass index; CRP: C-reactive protein; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; FiRST: Fibromyalgia Rapid Screening Tool; IBD: Inflammatory Bowel Disease; IBD-SpA: Inflammatory Bowel Disease associated Spondyloarthritis; Juv-SpA: Juvenile Spondyloarthritis; PGA: Patient's Global Assessment; PsA: Psoriatic Arthritis; pSpA: peripheral Spondyloarthritis; ReA: Reactive Arthritis; SD: Standard Deviation; SPARCC Enthesitis Index

Supplementary Figure S1. Natural history of the enthesitis in the past with regard to the diagnosis*.




*Among patients with enthesitis in the past (n = 1984).

AxSpA: axial Spondyloarthritis; IBD-SpA: Inflammatory Bowel Disease associated Spondyloarthritis; Juv-SpA: Juvenile Spondyloarthritis; PsA: Psoriatic Arthritis; pSpA: peripheral Spondyloarthritis; ReA: Reactive Arthritis.




Supplementary Figure S2. Number of locations of all episodes of enthesitis in the past with regard to the geographic area*.



Supplementary Figure S3. Number of locations of all episodes of enthesitis in the past with regard to the diagnosis*.

AxSpA: axial Spondyloarthritis; IBD-SpA: Inflammatory Bowel Disease associated Spondyloarthritis; Juv-SpA: Juvenile Spondyloarthritis; PsA: Psoriatic Arthritis; pSpA: peripheral Spondyloarthritis; ReA: Reactive Arthritis.



Supplementary Figure S4. Location of the dactylitis in the past with regard to the diagnosis*.

■ Only toes ■ Fingers and toes □ Only fingers

*Among patients with dactylitis in the past and available data concerning the location (n = 676).

AxSpA: axial Spondyloarthritis; IBD-SpA: Inflammatory Bowel Disease associated Spondyloarthritis; Juv-SpA: Juvenile Spondyloarthritis; PsA: Psoriatic Arthritis; pSpA: peripheral Spondyloarthritis; ReA: Reactive Arthritis.